Albireo Pharma Inc Stock News

BOSTON, April 30, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.

Albireo Pharma (NASDAQ:ALBO) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Saturday, BidAskClub reports. Other equities research

Goldman Sachs Group Inc. reduced its position in shares of Albireo Pharma Inc (NASDAQ:ALBO) by 66.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Sec

In a report released today, Alan Carr from Needham maintained a Buy rating on Albireo Pharma (ALBO – Research Report),

In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Albireo Pharma (ALBO – Research

Man Group plc lowered its stake in Albireo Pharma Inc (NASDAQ:ALBO) by 51.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional inve

BOSTON, April 07, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.

After Wedbush and Needham gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from William Blair.

After Wedbush and Needham gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced eff

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dum

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

On track to report topline data mid-2020 BOSTON, March 10, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing.

Albireo Pharma, Inc. (NASDAQ:ALBO) last week reported its latest yearly results, which makes it a good time for...

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Albireo Pharma ( ALBO – Research Report ) today and set a price target of $62.00 . The company’s shares closed last Monday at $24.22. Acc